CYCLE PHARMACEUTICALS LTD

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The company is a commercial pharmaceutical company that expects to generate significant operating profit during 2025 based on continued growth. Management's cash flow forecast for a twelve-month period confirms positive cashflow. Directors expect the company to continue as a going concern for more than twelve months from approval date.”

Group structure

1. CYCLE PHARMACEUTICALS LTD · parent
   1. Cycle Pharmaceutical Inc 100% · USA · promotion of pharmaceutical products and patient support

Significant events

• “On 1 January, 2024, Varsity Pharmaceuticals Limited transferred assets, liabilities, and its business operations to Cycle as part of an internal restructuring.”
• “Post year-end Cycle has expanded its portfolio of US drug products with the acquisition (through its wholly owned subsidiary) of Banner Life Sciences LLC (which brings the multiple sclerosis treatment BAFIERTAM into Cycle's portfolio).”
• “Post year-end Cycle has also expanded into haematology having recently signed a commercialisation agreement for a FDA-approved drug product that treats rare forms of leukaemia.”
• “In January 2025 CPL's wholly owned subsidiary, Cycle Pharmaceuticals Inc, acquired Banner Life Sciences LLC for initial cash consideration of $51.6m.”
• “Within the next 12 months Cycle intends to integrate the BAFIERTAM product acquired in the Banner Life Sciences acquisition and to launch new products across a variety of indications.”
• “Further commercialisation agreements, in-licensing of new products and M&A activity remain core to the Company's strategy.”
• “On 28 February 2025, the company approved an interim dividend of $12,000k to the parent company, Cycle Group Holdings Limited, which was settled on 28 February 2025.”
• “On 18 March 2025, a new branded generic product Venxxiva was launched in the US market which will contribute revenue in 2025.”
• “On 18 April 2025, the Group signed a commercialisation agreement with Handa Pharma to commercialise PHYRAGO in the US, an approved treatment for rare forms of leukaemia.”
• “On 9 May 2025, the Group signed a commercialisation agreement with Lupin Inc to launch a branded generic form of glycerol phenylbutyrate.”
• “On 29 May 2025, the company approved an interim dividend of $12,000k to the parent company, Cycle Group Holdings Limited, which was settled on 30 May 2025.”
• “On 10 June 2025 the FDA approved HARLIKU (nitisinone) for the treatment of Alkaptonuria (AKU) and first commercial sales are anticipated during H2 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.